postoperative adjuvant chemotherapy
PreclinicalSmall molecule
postoperative adjuvant chemotherapy is one of 41 small molecule programs targeting Small Cell Lung Cancer. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
598 competitors in Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Imfinzi
AstraZenecaPhase 3
Tecentriq
RochePhase 3
Keytruda
Merck & Co.Phase 3
Zepzelca
Jazz PharmaceuticalsPhase 3
Lenvima
EisaiPhase 3
Trodelvy
GileadPhase 3
Ifex
BBaxter Healthcare Corporation
Phase 3
Aranesp
AmgenPhase 3
Etopophos
GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH
Phase 3
Mesnex
BBaxter Healthcare Corporation
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- PPeng Zhang